MedChunk
Medically reviewed

How Long Do Biologics Take to Work for AS? Typical Timeline

Learn how long biologics take to work for ankylosing spondylitis, when symptoms may improve, typical response timelines, and when doctors consider changing treatment.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 11 min read

Biologics for ankylosing spondylitis (AS) may start improving symptoms within 2 to 4 weeks, although some people need 8 to 12 weeks or longer to notice meaningful relief. Most treatment plans include a formal review after about 12 weeks to check whether the medicine is working. The exact timeline depends on the type of biologic, the person's response, and the level of disease activity.

When do biologics start working for ankylosing spondylitis?

Biologics are medicines that target specific parts of the immune system involved in inflammation. In AS, they can help reduce inflammation in the spine and other affected joints, which may ease pain and stiffness.

Some people notice early changes within the first few weeks. Others improve gradually over several months. Early improvement does not necessarily mean the full benefit has been reached, so treatment response is usually assessed over a longer period.

According to the National Axial Spondyloarthritis Society (NASS), it can take up to three months or more to start feeling better after beginning biologic therapy.

Typical biologic treatment timeline for AS

Although there is no single schedule that applies to everyone, the following timeline provides a general idea of what may happen after starting treatment.

First 1 to 2 weeks: Early changes may begin

Some people experience an early reduction in pain, stiffness, or other inflammatory symptoms during the first couple of weeks. This can happen with certain medicines, including some TNF inhibitors.

However, not noticing a difference during this early period does not automatically mean the treatment will fail. The medicine may need more time to produce a noticeable improvement.

Weeks 2 to 4: Initial symptom improvement

During this period, some people begin to notice that their symptoms are becoming easier to manage. Possible changes include:

  • Less morning stiffness or stiffness that lasts for a shorter time.
  • Reduced back or buttock pain.
  • Improved comfort when moving after sitting or resting.
  • Better ability to carry out everyday activities.
  • Less disruption from symptoms during the night.

These improvements may appear gradually rather than all at once. Some people notice changes in pain before they experience better movement or daily function.

Weeks 4 to 8: Improvement may become clearer

For people who respond to treatment, improvements may become more noticeable over the next several weeks. Morning stiffness may become less troublesome, and everyday movement may feel more comfortable.

At this stage, keeping track of symptoms can help identify changes that are difficult to remember from one appointment to another. Recording morning stiffness, pain, sleep disruption, and activity levels may provide useful information for the rheumatology team.

Weeks 8 to 12: An important assessment period

By approximately three months, healthcare professionals generally have a better opportunity to assess whether a biologic is providing meaningful benefit.

The National Institute for Health and Care Excellence (NICE) recommends assessing the response to TNF-alpha inhibitors after 12 weeks. Continued treatment depends on clear evidence that the medicine is working.

This assessment is important because some early changes may be small, while a more meaningful improvement becomes apparent over time.

After 12 to 16 weeks: Further assessment for certain biologics

Not every biologic is assessed at exactly the same time. The recommended assessment period can depend on the medicine's mechanism of action.

The 2025 British Society for Rheumatology guideline recommends evaluating treatment response at a minimum of 12 weeks. It also identifies specific assessment periods of 16 weeks for secukinumab and bimekizumab, and 16 to 20 weeks for ixekizumab.

These differences are important when interpreting treatment progress. A medicine should not automatically be considered unsuccessful simply because it has not produced the same early response as another biologic.

How long do different biologics take to work for AS?

Biologics used for AS target different inflammatory pathways. Their response times and recommended assessment periods can therefore differ.

TNF inhibitors

TNF inhibitors block tumour necrosis factor (TNF), a protein involved in inflammation. Examples include:

  • Adalimumab
  • Etanercept
  • Infliximab
  • Golimumab
  • Certolizumab pegol

Some people notice improvement within the first few weeks, while others need longer. The usual formal response assessment for these medicines is around 12 weeks.

The NHS guidance on ankylosing spondylitis treatment explains that anti-TNF treatment is closely monitored and may be stopped if symptoms do not improve significantly after at least three months. A different medicine may then be considered.

IL-17 inhibitors

IL-17 inhibitors block interleukin-17, another protein involved in inflammation. Examples used in AS include:

  • Secukinumab
  • Ixekizumab
  • Bimekizumab

Some people experience improvement during the first several weeks, but the response assessment may take longer depending on the medicine. Current British guidance identifies a 16-week assessment for secukinumab and bimekizumab, and 16 to 20 weeks for ixekizumab.

These assessment periods help the treating specialist decide whether the medicine is providing enough benefit to continue.

What improvements should you notice when biologics work?

The aim of biologic treatment is to control inflammation and improve how a person feels and functions. A helpful response may involve several changes rather than one dramatic improvement.

Possible signs of improvement include:

  • Less morning stiffness: Getting out of bed and starting daily activities may become easier.
  • Reduced back pain: Pain associated with inflammation may become less frequent or intense.
  • Better sleep: Fewer interruptions from back discomfort may improve sleep quality.
  • Improved movement: Walking, bending, or changing positions may become more comfortable.
  • Better daily function: Work, household activities, and exercise may become easier to manage.
  • Reduced overall disease activity: The frequency and impact of inflammatory symptoms may decrease.

Not everyone experiences all these changes. A person may have less pain but still experience stiffness or reduced mobility. The overall response is therefore considered rather than relying on a single symptom.

How do doctors know whether a biologic is working?

Rheumatologists assess treatment response using a combination of patient feedback, physical examination, and appropriate clinical measurements.

Some of the information considered includes:

  • Symptom changes: Whether pain, morning stiffness, fatigue, and daily limitations have improved.
  • BASDAI score: The Bath Ankylosing Spondylitis Disease Activity Index measures aspects of disease activity using reported symptoms.
  • ASDAS score: The Ankylosing Spondylitis Disease Activity Score combines clinical information with laboratory markers such as C-reactive protein (CRP), when available.
  • Inflammation markers: Blood tests such as CRP may help assess inflammation, although normal results do not always mean that AS is inactive.
  • Physical function: Changes in movement, stiffness, and the ability to perform everyday tasks.

The 2025 British Society for Rheumatology guideline recommends assessing response using validated measures such as ASDAS, BASDAI, and spinal pain. It also emphasizes considering treatment effectiveness, tolerability, and the person's overall well-being.

Why might biologics take longer to work for some people?

There is no single reason why one person improves quickly while another needs more time. Several factors may influence the response or how noticeable the improvement feels.

The type of biologic

Different biologics target different inflammatory proteins. Their expected response and assessment periods are not identical. A treatment timeline should therefore be based on the specific medicine rather than a general expectation for all biologics.

The level of inflammation

The amount of active inflammation and the pattern of disease activity may influence how treatment progress is assessed. Persistent pain does not always mean that inflammation remains active, particularly when other factors may contribute to discomfort.

Other causes of pain or stiffness

Not all back pain in someone with AS necessarily comes from active inflammation. Mechanical back problems, muscle-related discomfort, and other conditions may contribute to ongoing symptoms.

This is why a rheumatologist may need to reassess the overall clinical picture when symptoms continue despite treatment.

Missed doses or treatment interruptions

Biologics need to be taken according to the prescribed schedule. Missed injections, delayed infusions, or interruptions may affect treatment continuity. If a dose is missed, the person should follow the medicine-specific instructions or contact their healthcare team rather than changing the schedule independently.

What if biologics are not working after three months?

If there is little or no meaningful improvement after the recommended assessment period, the rheumatologist may review the treatment plan. This does not necessarily mean that every biologic will fail.

The review may include:

  • Checking whether the medicine has been taken as prescribed.
  • Reassessing whether current symptoms are caused by active inflammation.
  • Reviewing disease activity scores and relevant examination or test findings.
  • Considering whether another condition is contributing to persistent pain.
  • Discussing whether a different biologic or treatment approach may be more suitable.

If a TNF inhibitor does not provide a sufficient response, another TNF inhibitor or a biologic targeting a different inflammatory pathway may be considered. The choice depends on previous treatment response, other health conditions, side effects, and clinical findings.

The 2025 British Society for Rheumatology guideline recommends reassessing the diagnosis and the extent of inflammatory disease activity when targeted treatment does not produce a response. An alternative targeted treatment may be appropriate when active disease continues.

Does a biologic provide permanent relief from AS?

Biologics can provide sustained control of AS symptoms in people who respond to treatment, but they do not cure the condition. Their main purpose is to reduce inflammatory disease activity and help maintain better daily function.

Some people experience long-lasting improvement while continuing their prescribed medicine. Others may have periods when symptoms return or treatment becomes less effective.

Stopping a biologic without medical guidance is not recommended because disease activity may increase again. Decisions about continuing, changing, or reducing treatment should be made with the rheumatologist.

When should you contact your rheumatologist?

Contact the treating team if symptoms are getting worse, new symptoms develop, or treatment is causing difficulties that interfere with taking it as prescribed.

It is also important to report possible infections while receiving biologic treatment. These medicines affect parts of the immune system, and some can increase the risk of infection. A serious infection or symptoms that need urgent medical attention should be assessed promptly.

Do not wait until the three-month review if you develop a concerning reaction or significant new symptoms. Your healthcare team can advise whether the next dose should be delayed or whether an assessment is needed.

Frequently Asked Questions

Common questions about biologic treatment timelines and expected improvements in ankylosing spondylitis.

Can biologics work for AS within two weeks?

Yes. Some people notice early improvement within two weeks, particularly with certain TNF inhibitors. However, others need several weeks or months. An early response does not necessarily represent the full treatment benefit.

How long should I wait before deciding that my AS biologic is not working?

For many TNF inhibitors, the formal response assessment takes place around 12 weeks. Some IL-17 inhibitors have assessment periods of 16 to 20 weeks, depending on the medicine. The appropriate timeline should be confirmed with the treating rheumatologist.

Is it normal to have pain after starting biologics for AS?

Yes. Pain may continue during the early weeks of treatment while the medicine begins to take effect. Persistent pain can also have causes other than active inflammation. If symptoms worsen or remain troublesome, discuss them with the rheumatology team.

Can biologics stop working after initially improving AS symptoms?

Yes. Some people experience a loss of treatment response over time. If symptoms return or disease activity increases, the rheumatologist may reassess the situation and consider another treatment.

Should I stop taking biologics if I do not feel better after one month?

No. One month may be too early to judge the full response, depending on the medicine. Continue following the prescribed treatment plan unless your healthcare professional advises otherwise. Contact the treating team if you have concerns about effectiveness or side effects.

Citations

  1. National Axial Spondyloarthritis Society (NASS) – Making Medication Decisions
  2. National Institute for Health and Care Excellence (NICE) – TNF-alpha Inhibitors for Ankylosing Spondylitis
  3. NHS – Ankylosing Spondylitis Treatment
  4. British Society for Rheumatology – 2025 Guideline for the Treatment of Axial Spondyloarthritis with Biologic and Targeted Synthetic DMARDs
Share this article